Buyout buzz swells for the giant Bristol-Myers after Carl Icahn makes an entrance, stage left
Carl Icahn, the aging activist who’s prodded a series of high-profile biopharma companies into the arms of eager buyers, has taken a stake in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
